Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Bristol-Myers Squibb Co — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.55 (market cap $2.14B), while Bristol-Myers Squibb Co trades at $63.93 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 60.7× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| AMC | BMY | |
|---|---|---|
Market Cap | $2.14B | $129.94B |
Sector | Media | Health |
52-Week High | $3.15 | $65.89 |
52-Week Low | $0.95 | $42.60 |
Enterprise Value | $9.08B | $163.92B |
Dividend Yield | 0.11% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.555, up 5.58% today, with a bullish technical signal and recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by strong box office performance and premium screen growth. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion as of 2024. Cash flow trends show improvement, with projected positive operating cash flow of $219 million in 2026.
Outlook is mixed; operational recovery and analyst consensus price target of $3.00 offer upside, but high debt and persistent losses pose significant risks. Investor sentiment is buoyed by record-breaking weekends and international expansion, yet volatility from meme-stock status and competitive pressures require caution.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
